DUBLIN–(BUSINESS WIRE)–The “Indian Pharmaceutical Contract Manufacturing Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The Indian pharmaceutical contract manufacturing market is anticipated to grow at a favourable CAGR of around 13.3% during the forecast period. Being one of the free trade agreement members, India holds the access to the best established and emerging pharmaceutical markets in the Asia-Pacific region.
Due to the favorable factors, such as low manufacturing cost, easy availability of skilled workers, and well-established certified plants, the Indian pharmaceutical contract manufacturing has witnessed higher growth in the forthcoming year. According to the FDA. Maharashtra.Gov, in India nearly 58 companies have certification including Emcure Pharmaceuticals Ltd. is certified with US FDA/WHO/Medical control council(MCC), and UK MHRA, and Cipla Ltd., is been certified with US FDA/ MHRA/ Therapeutic Control Council, and ANVISA(Brazil).
In basic manufacturing of medical drugs and devices, India has a superior edge over nations, such as Vietnam, China, and Ireland, owing to the availability of immense raw material, technical workforce, and WHO-approved production premises. During the COVID-19 pandemic, several initiatives were taken by the Union Cabinet to boost the Indian pharmaceutical industry, which includes the amendment of the existing foreign direct investment (FDI), which allows the foreign investors to invest up to 100% under the automatic route for manufacturing medical devices. With the advent of global pharmaceutical organizations, and their vast presence in India, the concept of contract manufacturing has steadily evolved, which in turn boosts the growth of India’s pharmaceutical contract manufacturing market.
Market Segmentation
The Report Covers
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Segmentation
5. Company Profiles
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/ewmosq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
HOHHOT, CHINA - Media OutReach Newswire - 7 November 2024 - In Q4 2024, the…
TAIPEI, TAIWAN - Media OutReach Newswire - 7 November 2024 - TVBS is a leading…
Redefining the Golden Years with “Care Food” HONG KONG SAR - Media OutReach Newswire -…
TAIPEI, TAIWAN - Media OutReach Newswire - 7 November 2024 - The UK's Competition and…
PHNOM PENH, CAMBODIA - Media OutReach Newswire - 7 November 2024 - The way people…
The facility caters to high-tech end-user industries, such as Aerospace, Healthcare, 5G, Artificial Intelligence (AI)…